Delivery Order SPE2DB22D2206-SPE2DB25FKA96
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 mL auto-injector pens on August 19, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (contract SPE2DX), valued at $999,999,999.00 and extending...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $19,218.06 to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Actemra ActPen 162 mg/0.9 mL auto-injectors. This is a firm fixed-price, non-competitive set-aside delivery order with an ultimate completion date of September 18, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under a larger...
- The Defense Logistics Agency awarded a $5,755.68 firm fixed-price delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This is a non-set-aside, competitively awarded contract with performance completion targeted for August 12, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a $11,794.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 8, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injectors. This competitively awarded contract, with no set-aside designation, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $21,626.20 delivery order to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This firm fixed-price delivery order, with an ultimate completion date of September 2, 2025, represents a competitive award with no set-aside designation. The pharmaceutical product will be delivered to the Place of Performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $15,757.28 to AmerisourceBergen Drug Corp for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. The contract, awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, is structured as a firm fixed-price delivery order with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector units. This firm fixed-price delivery order, valued at $6,863.64, represents a competitive award with no set-aside designation and is scheduled for completion by August 21, 2025. The award was issued to AmerisourceBergen's Corporate Office division, with performance to take place at the company's...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.93 to AmerisourceBergen Drug Corp for Actemra Actpen 162 mg/0.9 ml auto-injector pens. The contract was awarded on September 8, 2025, with an ultimate completion date of September 9, 2025, and employs firm fixed price terms with no set-aside designation. Performance will take place at AmerisourceBergen's corporate headquarters in Conshohocken, Pennsylvania. This delivery order is issued under the company's larger Indefinite...
- The Defense Logistics Agency awarded a $2,287.88 delivery order to AmerisourceBergen Drug Corp on September 24, 2025, for the supply of Actemra Actpen 162 mg/0.9 ml auto-injector pens. This competitively awarded, firm fixed-price contract carries an ultimate completion date of September 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order does not utilize a set-aside designation. This delivery order operates under...
- The Defense Logistics Agency awarded a delivery order valued at $1,143.94 to AmerisourceBergen Drug Corp for the supply of Actemra ActPen 162 mg/0.9 mL auto-injector pens. This firm fixed price delivery order was competitively awarded without set-aside designation and is scheduled for completion by September 9, 2025. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary operations as a major...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FKA96Delivery Order
The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $10,906.05 on September 22, 2025, for the supply of Actemra Actpen 162 mg/0.9 mL auto-injector pens. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The delivery order will be fulfilled from the contractor's facility in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. This delivery order exemplifies AmerisourceBergen's critical role as a pharmaceutical prime vendor to the Defense Logistics Agency's medical supply chain. As a major healthcare solutions provider, the contractor supplies a comprehensive portfolio of pharmaceutical products to support military healthcare programs and other federal medical systems. The Actemra product being delivered under this order is a biologic immunosuppressant used primarily for rheumatoid arthritis treatment, reflecting the breadth of specialty medications that AmerisourceBergen provides through its federal contract vehicle to ensure adequate medical supply availability for the Department of Defense and other government healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $10.9k | 9/22/25 |